CINECA IRIS Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Torino.
AperTO è l'archivio istituzionale Open Access destinato a raccogliere, rendere visibile e conservare la produzione scientifica dell'Università degli Studi di Torino.
ItalianoLAROCCA, Alessandra
Pubblicazioni
Risultati 1 - 20 di 84 (tempo di esecuzione: 0.001 secondi).
| Titolo | Data di pubblicazione | Autore(i) | |
|---|---|---|---|
| 1 | A PHASE III STUDY OF ENOXAPARIN VS ASPIRIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED OF MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE-BASED REGIMENS. | 2011 | F. CAVALLO; T. CARAVITA; F. DI RAIMONDO; G. CICCONE; B. LUPO; M. MARCATTI; A. BARALDI; N. PESCOSTA; A.P. FALCONE ;R. RIA; L. BALDINI; L. MASINI; T. GUGLIELMELLI; G. GAIDANO; G. BENEVOLO; C. CANGIALOSI ; M. GALLI ; L. CATALANO; A. LAROCCA; A. NAGLER; M. BOCCADORO; A. PALUMBO |
| 2 | A PROSPECTIVE RANDOMIZED TRIAL OF BORTEZOMIB-MELPHALANPREDNISONE-THALIDOMIDE FOLLOWED BY CONTINUOUS BORTEZOMIB-THALIDOMIDE FOR INITIAL THERAPY OF MULTIPLE MYELOMA:EFFECT OF AGE AND CO-MORBIDITIES | 2010 | A Palumbo; S Bringhen; D Rossi; M Cavalli; R Ria; M Offidani; C Nozzoli; L Baldini; L De Rosa; G De Sabbata; AM Liberati; C Crippa; F Ciambelli; V Callea; M Spriano; F Ferrara; F Elice; M Galli; J Peccatori; L Catalano; M Rizzo; R Marasca; F Pisani; M Cavo; M Petrucci; P Musto; P Omedè; A Larocca; G Gaidano; M Boccadoro |
| 3 | A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. | 2005 | Rossini F;Terruzzi E;Verga L;Larocca A;Marinoni S;Miccolis I;Giltri G;Isella M;Parma M;Pogliani EM |
| 4 | ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS | 2010 | F Gay; A Larocca; MT Petrucci; P Musto; AM Liberati; V Callea; R Ria; T Caravita; C Cangialosi; M Grasso; M Offidani; P Pregno; F Patriarca; M Galli; M Cavo; L Catalano; C Nozzoli; T Guglielmelli; R Zambello; F Pisani; V Montefusco; F Rossini; V De Stefano; B Lupo; F Di Raimondo; G Gaidano; M Boccadoro; A Palumbo |
| 5 | Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. | 2013 | Bringhen S;Mateos MV;Zweegman S;Larocca A;Falcone AP;Oriol A;Rossi D;Cavalli M;Wijermans P;Ria R;Offidani M;Lahuerta JJ;Liberati AM;Mina R;Callea V;Schaafsma M;Cerrato C;Marasca R;Franceschini L;Evangelista A;Teruel AI;van der Holt B;Montefusco V;Ciccone G;Boccadoro M;San Miguel J;Sonneveld P;Palumbo A |
| 6 | Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide | 2012 | Larocca A; Cavallo F; Bringhen S; Di Raimondo F; Falanga A; Evangelista A; Cavalli M; Stanevsky A; Corradini P; Pezzati S; Patriarca F; Cavo M; Peccatori J; Catalano L; Carella AM; Cafro AM; Siniscalchi A; Crippa C; Petrucci MT; Ben Yehuda D; Beggiato E; Caravita Di Toritto T; Boccadoro M; Nagler A; Palumbo A |
| 7 | Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. | 2006 | Larocca A;Piaggio G;Podestà M;Pitto A;Bruno B;Di Grazia C;Gualandi F;Occhini D;Raiola AM;Dominietto A;Bregante S;Lamparelli T;Tedone E;Oneto R;Frassoni F;Van Lint MT;Pogliani E;Bacigalupo A |
| 8 | Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. | 2014 | Mateos MV;Bringhen S;Richardson PG;Lahuerta JJ;Larocca A;Oriol A;Boccadoro M;García-Sanz R;Di Raimondo F;Esseltine DL;van de Velde H;Desai A;Londhe A;San Miguel JF;Palumbo A |
| 9 | Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: A multicenter, open label phase 1/2 study. | 2012 | Petrucci MT; Levi A; Bringhen S; Scotti S; Gentilini F; Russo S; Siniscalchi A; Larocca A; Grammatico S; Boccadoro M; Foà R; Palumbo A. |
| 10 | Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study. | 2013 | Petrucci MT;Levi A;Bringhen S;Scotti S;Gentilini F;Russo S;Siniscalchi A;Larocca A;Grammatico S;Boccadoro M;Foà R;Palumbo A |
| 11 | Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. | 2014 | Morabito F;Bringhen S;Larocca A;Wijermans P;Victoria Mateos M;Gimsing P;Mazzone C;Gottardi D;Omedè P;Zweegman S;José Lahuerta J;Zambello R;Musto P;Magarotto V;Schaafsma M;Oriol A;Juliusson G;Cerrato C;Catalano L;Gentile M;Isabel Turel A;Marina Liberati A;Cavalli M;Rossi D;Passera R;Rosso S;Beksac M;Cavo M;Waage A;San Miguel J;Boccadoro M;Sonneveld P;Palumbo A;Offidani M |
| 12 | Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m2 in Elderly Newly Diagnosed Patients: An Interim Analysis. | 2007 | Palumbo A; Avonto I; Patriarca F; Crippa C; Petrucci MT; Rossini F; Corradini P; Liberati AM; Giuliani N; Pescosta N; Falco P; Larocca A; Omedè P; Offidani M; Fanin R; Boccadoro M |
| 13 | Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study | 2020 | Mina R.; Belotti A.; Petrucci M.T.; Zambello R.; Capra A.; Di Lullo G.; Ronconi S.; Pescosta N.; Grasso M.; Monaco F.; Cellini C.; Gobbi M.; Ballanti S.; de Fabritiis P.; Mosca-Siez M.L.; Marchetti M.; Liberati A.M.; Offidani M.; Giuliani N.; Ria R.; Musto P.; Romano A.; Sonneveld P.; Boccadoro M.; Larocca A. |
| 14 | Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. | 2010 | Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Pia Falcone A; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M. |
| 15 | Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. | 2014 | Palumbo A;Bringhen S;Larocca A;Rossi D;Di Raimondo F;Magarotto V;Patriarca F;Levi A;Benevolo G;Vincelli ID;Grasso M;Franceschini L;Gottardi D;Zambello R;Montefusco V;Falcone AP;Omedé P;Marasca R;Morabito F;Mina R;Guglielmelli T;Nozzoli C;Passera R;Gaidano G;Offidani M;Ria R;Petrucci MT;Musto P;Boccadoro M;Cavo M |
| 16 | Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) | 2018 | Sara Bringhen, Alberto Milan, Claudio Ferri, Ralph Wäsch, Francesca Gay, Alessandra Larocca, Marco Salvini, Evangelos Terpos, Hartmut Goldschmidt, Michele Cavo, Maria Teresa Petrucci, Heinz Ludwig, Holger W. Auner, Jo Caers, Martin Gramatzki, Mario Boccadoro, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt |
| 17 | Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. | 2014 | Bringhen S;Petrucci MT;Larocca A;Conticello C;Rossi D;Magarotto V;Musto P;Boccadifuoco L;Offidani M;Omedé P;Gentilini F;Ciccone G;Benevolo G;Genuardi M;Montefusco V;Oliva S;Caravita T;Tacchetti P;Boccadoro M;Sonneveld P;Palumbo A |
| 18 | Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino | 2019 | Gian Maria Zaccaria, Daniela Drandi, Simona Caltagirone, Martina Ferrante, Marco Ghislieri, Daniela Barbero, Marina Ruggeri, Barbara Mantoan, Elisa Genuardi, Daniela Oddolo, Giuseppe Lia, Valentina Griggio, Pierpaola Fenoglio, Mattia D’Agostino, Candida Vitale, Marta Coscia, Benedetto Bruno, Stefania Oliva, Paola Omedè, Alessandra Larocca, Simone Ferrero, Mario Boccadoro |
| 19 | Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma | 2020 | Oliva S.; D'Agostino M.; Boccadoro M.; Larocca A. |
| 20 | Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. | 2011 | Gay F; Larocca A; Wijermans P; Cavallo F; Rossi D; Schaafsma R; Genuardi M; Romano A; Liberati AM; Siniscalchi A; Petrucci MT; Nozzoli C; Patriarca F; Offidani M; Ria R; Omedè P; Bruno B; Passera R; Musto P; Boccadoro M; Sonneveld P; Palumbo A. |
Dettaglio
LAROCCA, Alessandra
BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE
Copyright © 2020